Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its participation in three upcoming healthcare conferences in late February and early March 2026. President and CEO Jasbir S. Seehra, Ph.D., will present at these events, which include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 46th Annual Health Care Conference, and Leerink Partners Global Healthcare Conference. The company focuses on developing therapeutics for disorders linked to dysfunctional TGF-ß family protein signaling.
Keros Therapeutics CEO to Present at Multiple Conferences
Keros Therapeutics (KROS) announced that its President and CEO, Jasbir S. Seehra, will present at three major healthcare investor conferences in late February and early March 2026. The company aims to boost investor visibility and engagement by discussing its clinical pipeline and strategic direction. TipRanks' AI Analyst, Spark, rates KROS as "Neutral," citing improving financials and a strong balance sheet, but tempered by weaker near-term technical momentum.
Keros CEO to speak at Oppenheimer, TD Cowen and Leerink events
Keros Therapeutics (Nasdaq: KROS) announced that its CEO, Jasbir S. Seehra, Ph.D., will participate in three upcoming healthcare conferences in late February and March 2026. He will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference. Archived replays of these presentations will be available on the company's investor website for 90 days following each event.
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday
Keros Therapeutics (KROS) is anticipated to release its Q4 2025 earnings before market open on Wednesday, February 25th, with analysts forecasting a loss of ($0.49) per share. The company will host an earnings call on February 27th at 4:00 PM ET. KROS currently holds a "Hold" consensus rating from analysts with an average price target of $22.29, and its stock has shown institutional interest with several firms boosting their stakes.
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at three upcoming healthcare conferences in February and March 2026. These include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 46th Annual Health Care Conference, and Leerink Partners Global Healthcare Conference. The presentations will cover corporate updates and fireside chats, with archived replays available on the Keros website.
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
Keros Therapeutics (KROS) is expected to report its fourth-quarter results soon, with investors focusing on pipeline updates rather than product sales, as the company generates revenue primarily from a collaboration with Takeda Pharmaceuticals. KROS has a strong earnings surprise history and a Zacks Rank #3. Key pipeline candidates include rinvatercept for Duchenne muscular dystrophy and elritercept for myelodysplastic syndromes, with significant progress and strategic adjustments made to streamline operations and enhance capital efficiency.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts
Ten analysts have issued a "Hold" consensus rating for Keros Therapeutics, Inc. (NASDAQ:KROS), with an average one-year price target of $22.29. The company, a clinical-stage biopharmaceutical firm focusing on therapies for erythropoiesis and iron regulation disorders, saw its stock open at $16.58. Institutional investors, including Vanguard and Goldman Sachs, hold a significant ownership stake in Keros Therapeutics, which is developing its lead product candidate, KER-050.
Keros Therapeutics: Key Catalysts and Financial Runway in Focus
Keros Therapeutics is nearing significant clinical and financial milestones, with investors eagerly awaiting quarterly results on February 25 or March 4. A key catalyst includes the planned Q1 2026 initiation of a Phase 2 study for KER-065 in Duchenne muscular dystrophy. The company also continues its Phase 3 RENEW study for elritercept under a collaboration with Takeda Pharmaceuticals and reports sufficient cash reserves to fund operations into the first half of 2028.
Price-Driven Insight from (KROS) for Rule-Based Strategy
This article provides a price-driven analysis for Keros Therapeutics Inc. (NASDAQ: KROS), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels across different time horizons.
Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS
Y Intercept Hong Kong Ltd significantly reduced its stake in Keros Therapeutics (NASDAQ:KROS) by 53.7% in Q3, selling 56,333 shares and now holding 48,545 shares valued at $768,000. Despite this, Keros Therapeutics reported a strong quarter, beating EPS expectations and achieving 3,585.6% year-over-year revenue growth. Wall Street analysts currently hold a "Hold" consensus rating for KROS with a $22.29 average price target.
Keros Therapeutics, Inc. $KROS Shares Sold by Federated Hermes Inc.
Federated Hermes Inc. significantly reduced its stake in Keros Therapeutics, Inc. by 21.4%, selling 139,870 shares. Despite this, other institutional investors have increased their positions. The company recently reported strong quarterly earnings, beating revenue and EPS estimates, while analysts maintain a consensus "Hold" rating with an average target price of $22.29.
Is KROS' KER-065 the Next Breakthrough in DMD Space?
Keros Therapeutics (KROS) is developing KER-065, a lead pipeline candidate for Duchenne muscular dystrophy (DMD), which selectively inhibits TGF-β ligands to promote muscle and bone health. KER-065 has received orphan drug designation from the FDA, and Keros plans to start a Phase II trial in Q1 2026, redirecting resources after discontinuing another program. The article also details the competitive DMD treatment landscape, highlighting key players like Sarepta Therapeutics and PTC Therapeutics.
(KROS) Price Dynamics and Execution-Aware Positioning
This article provides an AI-generated analysis of Keros Therapeutics Inc. (NASDAQ: KROS), identifying a neutral near- and mid-term outlook but a positive long-term bias. It outlines detailed trading strategies for various risk profiles, including long, breakout, and short positions, along with corresponding entry zones, targets, and stop losses. The analysis highlights an exceptional risk-reward setup targeting an 11.2% gain against a 0.3% risk.
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring a Promising 20.76% Potential Upside
Keros Therapeutics (NASDAQ: KROS) is a clinical-stage biopharmaceutical company showing significant potential with a 20.76% analyst-projected upside. Despite a negative forward P/E, which is common for R&D-heavy biotech firms, Keros boasts impressive revenue growth of 3,575.80% and a robust therapeutic pipeline targeting serious conditions. Positive analyst sentiment, solid financial health, and a strategic collaboration further underscore its attractiveness to investors.
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages
Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus "Hold" rating from ten research firms, with an average 12-month price target of $22.2857. This rating includes one sell, four hold, and five buy recommendations. Recent analyst activity has been mixed, with some firms raising price targets and others cutting them, while the company reported strong Q3 earnings, exceeding revenue and EPS estimates.
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Marker Therapeutics (MRKR) shares have climbed nearly 114% in three months due to positive momentum from its lead candidate, MT-601, for relapsed or refractory B-cell lymphoma. Data from the APOLLO study showed encouraging responses and a favorable safety profile, leading to progression into a dose expansion phase. The company also secured funding, extended its cash runway, advanced its MT-401 program, and plans to initiate MT-601 studies for pancreatic cancer.
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia
Axsome Therapeutics has initiated a Phase III study, FORWARD, for its investigational drug, AXS-14 (esreboxetine), to treat fibromyalgia following a prior Refusal to File letter from the FDA. The study aims to address regulatory feedback regarding the adequacy of previous trials and will evaluate AXS-14's ability to reduce chronic pain by increasing norepinephrine levels. Concurrently, Axsome plans to submit an NDA for AXS-12 for narcolepsy in late January 2026.
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
Keros Therapeutics (KROS) is undergoing significant restructuring, discontinuing its cibotercept program to focus solely on KER-065 for neuromuscular disorders, particularly Duchenne muscular dystrophy (DMD). This shift involved a 45% workforce reduction and is expected to yield $17 million in annual cost savings. The company’s financial position is strong with $693.5 million in cash, projected to fund operations until mid-2028, and its stock has significantly outperformed the industry.
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
CG Oncology (CGON) shares have rallied nearly 32% in the past week, driven by the announcement that top-line data from its phase III PIVOT-006 study for bladder cancer is expected in the first half of 2026, nearly a year earlier than projected. This accelerated timeline and positive late-stage data from another study (BOND-003) have boosted investor confidence regarding eventual regulatory approval. The company is evaluating its oncolytic immunotherapy, cretostimogene, for various bladder cancer indications, with no current FDA-approved therapies for intermediate-risk non-muscle invasive bladder cancer after surgery.
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?
Keros Therapeutics (KROS) has seen its stock skyrocket 85.6% in the past year, outperforming the industry and S&P 500, driven by strategic reviews and promising pipeline progress, especially with its lead candidate KER-065 for Duchenne muscular dystrophy. The company has also streamlined operations and secured significant funding through a licensing agreement with Takeda, positioning it with sufficient capital into the first half of 2028. Despite the challenging biotech sector, KROS exhibits a strong buy rating from Zacks due to its valuation and clinical advancements, with further upside potential hinging on positive clinical and regulatory updates for KER-065.
(KROS) as a Liquidity Pulse for Institutional Tactics
Keros Therapeutics Inc. (NASDAQ: KROS) is analyzed for institutional trading strategies, revealing a positive near-term sentiment while a weak bias is noted in the mid-term within a long-term strength context. The analysis highlights a 43.2:1 risk-reward setup, targeting an 11.5% gain versus 0.3% risk, and provides three distinct AI-generated trading strategies tailored for different risk profiles. These strategies include position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by Zacks Research
Zacks Research downgraded Keros Therapeutics (NASDAQ:KROS) from a "strong-buy" to a "hold" rating, citing mixed analyst opinion and significant insider selling. Despite a strong quarterly beat in revenue and EPS, analysts remain divided on price targets, and the stock's consensus rating is now "Hold." Major shareholders Adar1 Capital and Pontifax Management sold large blocks of shares in October, while institutional investors have recently modified their holdings.
KROS or ARGX: Which Is the Better Value Stock Right Now?
Keros Therapeutics (KROS) and argenex SE (ARGX) are evaluated as potential value stock opportunities in the Medical - Biomedical and Genetics sector. KROS, with a Zacks Rank of #1 (Strong Buy) and a Value grade of A, appears to be the superior option due to stronger earnings estimate revisions and more attractive valuation metrics like a forward P/E of 9.16 and a PEG ratio of 0.25, compared to ARGX's Zacks Rank of #3 (Hold) and Value grade of C.
Assenagon Asset Management S.A. Has $4.07 Million Holdings in Keros Therapeutics, Inc. $KROS
Assenagon Asset Management S.A. significantly increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 154.2% in Q3, now holding 257,518 shares valued at approximately $4.07 million. This comes as institutional investors collectively own about 71.56% of the company's stock, despite major shareholders selling off large positions in mid-October. Keros Therapeutics recently reported a substantial quarterly earnings beat, with EPS of ($0.18) against an expected ($1.11), and revenue of $14.26 million, far exceeding expectations and representing a massive year-over-year increase.
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher
Keros Therapeutics (KROS) has recently formed a hammer chart pattern, signaling a potential trend reversal after a 5.8% loss in the past week. This technical indicator, combined with strong fundamental backing from Wall Street analysts who have raised earnings estimates and a Zacks Rank #1 (Strong Buy), suggests KROS could be an excellent choice for investors looking for a bottom-fishing opportunity. The company's prospects for better future earnings are supported by the consensus among analysts and its position in the top 5% of ranked stocks.
Keros Therapeutics (NASDAQ:KROS) Upgraded at TD Cowen
TD Cowen upgraded Keros Therapeutics (NASDAQ:KROS) to a "hold" rating, contributing to a "Moderate Buy" consensus among analysts with a $21.38 average price target. The company recently reported strong earnings, beating expectations with an EPS of ($0.18) versus a consensus of ($1.11) and revenue of $14.26 million. Despite recent large-stake sales by major shareholders, institutional investors hold 71.56% of the stock.
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares
Keros Therapeutics has initiated a tender offer to repurchase up to $194.4 million of its common shares. This move aims to return capital to shareholders and potentially boost share value.
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc.
Federated Hermes Inc. significantly reduced its stake in Keros Therapeutics (NASDAQ:KROS) by 46.6% in the second quarter, representing a sale of 570,109 shares. Despite this, Keros Therapeutics posted strong quarterly results, beating EPS and revenue estimates, and holds a "Moderate Buy" consensus rating from analysts with an average price target of $21.38. Major shareholders sold large blocks of shares in October, raising approximately $180 million in proceeds.
Responsive Playbooks and the KROS Inflection
This article examines Keros Therapeutics Inc. (NASDAQ: KROS), highlighting a prevailing positive near and mid-term sentiment that could extend long-term despite elevated downside risk and no clear price positioning signal. It provides specific AI-generated institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis outlining support and resistance levels.
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
Keros Therapeutics, Inc. (KROS) is identified as a strong momentum stock with a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of B. The article highlights KROS's significant short-term and long-term price performance, outperforming its industry and the S&P 500, along with positive analyst earnings estimate revisions. These factors suggest that KROS is a promising pick for investors looking for near-term growth.
Keros Therapeutics (KROS): Valuation Check After Sharp Share Price Rebound and Ongoing Revenue Contraction Forecasts
Keros Therapeutics (KROS) has experienced a significant share price rebound, jumping 30% in the past month, despite Wall Street forecasting a 40% annual revenue contraction. The company's price-to-earnings ratio of 6.6x suggests it is undervalued compared to the broader market and biotech peers, but investors should consider the risks, including steep annual revenue and net income declines.
Stocks to watch: Keros Therapeutics sees relative strength rating rise to 82
Keros Therapeutics (KROS) has seen its IBD Relative Strength Rating improve to 82, placing it in the top 18% of all stocks. The biotechnology firm reported a 47% increase in earnings per share last quarter and maintains a strong Accumulation/Distribution Rating of B-. Investors should monitor its ongoing drug development and market performance.
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages
Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus "Hold" rating from fifteen brokerages, with an average 12-month price target of $30.33. Recent insider activity shows major shareholders selling significant blocks of shares, yet insiders still own 22.90% of the company. Despite beating Q3 earnings and revenue estimates, analysts forecast a full-year EPS of -$4.74.
There's No Escaping Keros Therapeutics, Inc.'s (NASDAQ:KROS) Muted Revenues Despite A 30% Share Price Rise
Keros Therapeutics' share price has risen 30% in the last month, but it's still down 71% over the past year. The company's low price-to-sales (P/S) ratio of 1.6x, significantly below the biotech industry average, suggests investors are concerned about its future revenue. Analysts forecast a 40% annual revenue contraction for Keros Therapeutics over the next three years, contrasting sharply with the industry's projected 128% annual growth, thus justifying the low P/S ratio.
Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer
Keros Therapeutics announced preliminary results for its cash tender offer, which concluded its $375 million capital return program. The company expects to repurchase approximately 10.95 million shares at $17.75 per share, totaling $194.4 million. This represents about 35.91% of outstanding common stock, with final confirmation pending from the Depositary.
Latham & Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer
Latham & Watkins LLP represented the dealer manager in Keros Therapeutics, Inc.'s cash tender offer to repurchase shares of its common stock. The biopharmaceutical company repurchased 10,950,165 shares at US$17.75 per share, totaling US$194.4 million, concluding its US$375 million capital return program. The legal team included partners Greg Rodgers, Nathan Ajiashvili, and Eric Cho.
Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares
Keros Therapeutics successfully completed its cash tender offer, repurchasing 10,950,165 shares at $17.75 each, totaling approximately $194.4 million. This action represents about 35.91% of outstanding common stock and concludes the company's previously announced $375 million capital return program. The tender offer saw 17,712,262 shares tendered, resulting in a proration factor of approximately 62.30%.
Keros Therapeutics Announces Final Results of Tender Offer
Keros Therapeutics announced the final results of its cash tender offer, repurchasing 10,950,165 shares of common stock at $17.75 per share, totaling approximately $194.4 million. The tender offer, which expired on November 18, 2025, concludes the company's $375 million capital return program. Due to oversubscription, shares were accepted on a pro rata basis with a final proration factor of approximately 62.30%.
Keros Therapeutics reports oversubscribed $194.4 million tender offer
Keros Therapeutics announced an oversubscribed cash tender offer to repurchase approximately $194.4 million of its common stock, part of a $375 million capital return program. The company will buy 10,950,165 shares at $17.75 each, representing about 35.91% of its outstanding common stock, with shares accepted on a pro rata basis due to oversubscription. Keros also has positive clinical developments for its drug candidates KER-065 and elritercept, and its financials show strong liquidity and potential for sales growth.
Keros Therapeutics Announces Preliminary Results of Tender Offer
Keros Therapeutics announced the preliminary results of its cash tender offer to repurchase up to 10,950,165 shares of its common stock at $17.75 per share, totaling approximately $194.4 million. The offer, which expired on November 18, 2025, concludes the company's $375 million capital return program. Due to over-tendering, Keros expects to accept shares on a pro rata basis, with the final number of purchased shares pending confirmation.
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%
Keros Therapeutics (NASDAQ:KROS) has seen a 26% share price jump recently but still faces challenges due to a 68% drop over the last year and concerns about future revenue growth. Despite strong past revenue performance, analysts project a 40% annual decline over the next three years, contrasting sharply with the broader industry's expected 121% growth. This negative outlook contributes to the company's low price-to-sales (P/S) ratio compared to industry peers, indicating investor skepticism about its ability to maintain current prices without an improved revenue trajectory.
McDermott represents ADAR1 Capital Management, LLC in its agreement with Keros Therapeutics, Inc.
McDermott Will & Schulte represented ADAR1 Capital Management, LLC in their agreement with Keros Therapeutics, Inc., which resulted in a significant return of capital to Keros shareholders. Keros announced an agreement to repurchase ADAR1 Capital’s entire stake, a public tender offer, and a commitment to distribute 25% of net cash proceeds from a licensing agreement with Takeda Pharmaceuticals U.S.A., Inc. This agreement followed ADAR1 Capital’s “withhold” campaign at Keros’ 2025 Annual Meeting of Stockholders.
Keros Therapeutics launches $194.4 million share repurchase tender offer
Keros Therapeutics, Inc. (NASDAQ:KROS) has initiated a tender offer to repurchase up to $194.4 million of its common stock at $17.75 per share, a 28% premium over its current trading price. This move is part of the company's $375 million capital return program and is supported by its strong financial position, including a significant cash reserve and a high current ratio. The offer is scheduled to expire on November 18, 2025, and coincides with the company's ongoing clinical development of KER-065 for Duchenne muscular dystrophy.
$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025
Keros Therapeutics (Nasdaq: KROS) has commenced a cash tender offer to repurchase up to $194.4 million of its common stock at $17.75 per share, as part of a larger $375 million capital return program. The offer, which is funded from existing cash, is set to expire on November 18, 2025. Neither the company nor its board has made a recommendation to shareholders regarding the offer.
Keros Therapeutics (NASDAQ:KROS) Major Shareholder Sells $84,975,125.25 in Stock
Pontifax Management 4 G.P., a major shareholder in Keros Therapeutics (NASDAQ:KROS), sold over 4.7 million shares totaling approximately $84.98 million. This transaction occurred on October 15th at an average price of $17.75 per share. Keros Therapeutics recently surpassed analyst earnings per share estimates, despite lower-than-forecasted revenues, and maintains a consensus target price of $30.00 from analysts.
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com
This article highlights the expanding market outlook for Sarcopenia treatments, projecting a significant increase from an estimated USD 2,276 million in 2025 to USD 5,626 million by 2034. It details key clinical trial advancements, regulatory approvals like Fast Track Designation, and lists prominent pharmaceutical companies and therapies in development aimed at addressing age-related muscle weakness. The report also provides epidemiological data, forecasting a rise in diagnosed Sarcopenia cases across major markets.
Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m By Investing.com - Investing.com Australia
Entities associated with Pontifax Funds sold a combined total of 4,784,631 shares of Keros Therapeutics (NASDAQ:KROS) for over $84.97 million on October 15, 2025, with sales executed at $17.75 per share. Following these transactions, the Pontifax entities no longer directly own KEROS shares. This divestiture follows Keros Therapeutics' recent share repurchase program and developments in its KER-065 drug candidate for Duchenne muscular dystrophy.
Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m By Investing.com - Investing.com Australia
Pontifax funds have sold shares of Keros Therapeutics (KROS) worth $84.97 million. This transaction indicates significant insider activity for the biotechnology company. Further details on the sale would typically involve the number of shares and the price per share, which are not provided in this snippet due to an application error.
Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m - Investing.com
This article reports a client-side exception preventing the main content from loading. Therefore, details about Pontifax funds selling Keros Therapeutics (KROS) shares for $84.97m are unavailable. The current content is limited to navigation elements and error messages.
Keros Therapeutics, Inc. (NASDAQ:KROS) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Keros Therapeutics, Inc. (NASDAQ:KROS) has a low price-to-sales (P/S) ratio of 2.5x, significantly lower than the biotech industry average, despite recent strong revenue growth. However, this low P/S ratio is likely influenced by analysts' predictions of a 43% annual revenue decrease over the next three years, contrasting sharply with the industry's projected 127% growth per annum. Consequently, the company's valuation appears inexpensive, but its unattractive future revenue outlook suggests limited potential for a strong share price increase.
